Phase 4Completed

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study

Sponsor
AstraZeneca (Industry)
Enrollment
633 enrolled
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets; Dapagliflozin tablets and Metformin HCl extended-release tablets
Ages
adults, older adults
Registry
NCT06327815

Full record on ClinicalTrials.gov

From the registry

Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM.

Primary outcomes

  • Change in HbA1c from baseline

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started

Papers citing this trial